TOPLINE: Deucravacitinib (Sotyktu) demonstrated efficacy in treating patients with active psoriatic arthritis (PsA), achieving higher American College of Rheumatology (ACR) 20 response rates (ie, ≥ 20% improvement in disease signs and symptoms) than placebo at week 16, with a consistent overall safety profile. METHODOLOGY: Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, represents a […]
The post Deucravacitinib Meets Endpoints in Phase 3 PsA Trial first appeared on News Health.
Author : News Health
Publish date : 2025-03-12 12:39:00
Copyright for syndicated content belongs to the linked Source.